Format

Send to

Choose Destination
J Cancer Res Clin Oncol. 2017 May;143(5):783-791. doi: 10.1007/s00432-016-2326-x. Epub 2017 Feb 18.

Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.

Author information

1
A.O. San Camillo Forlanini, Rome, Italy. ritamigliorino@tiscali.it.
2
Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
3
Ospedale V. Fazzi, Lecce, Italy.
4
Ospedale San Gerardo, Monza, Italy.
5
Istituto Tumori "Giovanni Paolo II" I.R.C.C.S., Bari, Italy.
6
A.O.U. Maggiore della Carità, Novara, Italy.
7
A.O.R.N. Antonio Cardarelli, Naples, Italy.
8
Istituto Regina Elena, Rome, Italy.
9
A.O.U. Santa Maria della Misericordia, Udine, Italy.
10
Ospedale Civile SS. Annunziata, Sassari, Italy.
11
Istituto Oncologico del Mediterraneo, Viagrande, Italy.
12
Fondazione Poliambulanza, Brescia, Italy.
13
A.O. Spedali Civili, Brescia, Italy.
14
Università La Sapienza, Rome, Italy.
15
Boehringer Ingelheim Italia Spa, Milan, Italy.
16
Istituto Europeo di Oncologia, Milan, Italy.

Abstract

PURPOSE:

Non-small cell lung cancer (NSCLC) is a condition with significant clinical burden for patients and relevant economic impact. Limited evidence exists on the management costs of NSCLC patients, especially in the late phases of the disease. The main objective of this analysis was to evaluate the economic impact of clinical management of NSCLC patients in the Italian population.

METHODS:

This evaluation was an economic analysis of the observational and multicentre study LIFE, which described the therapeutic approach in routine clinical practice for NSCLC patients, progressing after first-line treatment. This study evaluated resource consumption in different Italian hospitals, including specialist visits, hospitalizations, accesses to first aid, pharmacological treatment, laboratory tests and palliative care. The National Healthcare Service perspective was adopted.

RESULTS:

In this study, N = 191 patients enrolled in the LIFE study were included. Patients were aged 64.2 years and were predominantly males (66%). In the different line of treatments, monthly costs of patients ranged between €1471 (first line) and €1788 (third line). The overall healthcare cost over the average period of observation (16.4 months) was €25,859 per patient. Overall, oncology therapy was the cost driver, although the composition of medical costs changed across the different lines of treatment, with costs for concomitant medication and palliative care being predominant in late phase of the disease.

CONCLUSIONS:

The economic burden of NSCLC is extremely high during the overall period of treatment, and a significant level of care is required in each stage of the disease.

KEYWORDS:

Cost per line of treatment; Economic burden; Line of treatment; Non-small cell lung cancer; Observational study

PMID:
28215027
DOI:
10.1007/s00432-016-2326-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center